NASDAQ:QDEL QuidelOrtho (QDEL) Stock Forecast, Price & News $70.90 -0.66 (-0.92%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$70.67▼$71.9250-Day Range$70.90▼$88.6352-Week Range$66.88▼$102.00Volume475,121 shsAverage Volume460,774 shsMarket Capitalization$4.74 billionP/E Ratio107.43Dividend YieldN/APrice Target$119.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability QuidelOrtho MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside69.0% Upside$119.83 Price TargetShort InterestHealthy3.71% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.76Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth9.07%From $4.96 to $5.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.91 out of 5 starsMedical Sector50th out of 964 stocksDiagnostic Substances Industry1st out of 13 stocks 3.4 Analyst's Opinion Consensus RatingQuidelOrtho has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.83, QuidelOrtho has a forecasted upside of 69.0% from its current price of $70.90.Amount of Analyst CoverageQuidelOrtho has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.71% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in QuidelOrtho has recently decreased by 6.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.Environmental SustainabilityThe Environmental Impact score for QuidelOrtho is -2.61. Previous Next 3.2 News and Social Media Coverage News SentimentQuidelOrtho has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for QuidelOrtho this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions93.87% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for QuidelOrtho are expected to grow by 9.07% in the coming year, from $4.96 to $5.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is 107.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.15.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is 107.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.94.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About QuidelOrtho (NASDAQ:QDEL) StockQuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.Read More QDEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QDEL Stock News HeadlinesSeptember 26, 2023 | money.usnews.comQuidelOrtho CorporationSeptember 21, 2023 | finance.yahoo.comQuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIASeptember 27, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 21, 2023 | finance.yahoo.comShould You Add QuidelOrtho (QDEL) to Your Portfolio?September 20, 2023 | americanbankingnews.comQuidelOrtho's (QDEL) Outperform Rating Reaffirmed at Royal Bank of CanadaSeptember 19, 2023 | benzinga.comWhere QuidelOrtho Stands With AnalystsSeptember 19, 2023 | msn.comRBC Capital Reiterates QuidelOrtho (QDEL) Outperform RecommendationSeptember 19, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Regulus (RGLS), Ambrx Biopharma (AMAM)September 27, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 28, 2023 | finance.yahoo.comQuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 17, 2023 | msn.comDown -14% in 4 Weeks, Here's Why You Should You Buy the Dip in QuidelOrtho (QDEL)August 15, 2023 | markets.businessinsider.comAnalyst Is Frustrated By QuidelOrtho's Reduction In Guidance - Here's WhyAugust 10, 2023 | seekingalpha.comQuidelOrtho Corporation 2023 Q2 - Results - Earnings Call PresentationAugust 9, 2023 | msn.comQuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View RevisedAugust 8, 2023 | finance.yahoo.comQuidelOrtho (QDEL) Reports Q2 Earnings: What Key Metrics Have to SayAugust 8, 2023 | finance.yahoo.comQuidelOrtho Reports Second Quarter 2023 Financial ResultsAugust 7, 2023 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on QuidelOrtho (QDEL)July 24, 2023 | finance.yahoo.comQuidelOrtho Partners With BYG4lab® to Strengthen Informatics OfferingsJuly 24, 2023 | msn.comWall Street Analysts Believe QuidelOrtho (QDEL) Could Rally 29.87%: Here's is How to TradeJuly 19, 2023 | finance.yahoo.comThe three-year shareholder returns and company earnings persist lower as QuidelOrtho (NASDAQ:QDEL) stock falls a further 3.2% in past weekJuly 18, 2023 | finance.yahoo.comQuidelOrtho to Report Second Quarter 2023 Financial ResultsJuly 18, 2023 | finance.yahoo.comAre Investors Undervaluing QuidelOrtho (QDEL) Right Now?July 13, 2023 | seekingalpha.comQuidelOrtho: Mapping A Future As Covid Revenues Move To Endemic PhaseJuly 13, 2023 | seekingalpha.comQuidelOrtho: A Tough Call To Make Right NowJuly 4, 2023 | wsj.comQuidelOrtho Corp.June 12, 2023 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About QuidelOrtho Corporation (NASDAQ:QDEL)?June 11, 2023 | uk.finance.yahoo.comQL1A.F - QuidelOrtho CorporationSee More Headlines Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:QDEL CUSIP74838J10 CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,000Year Founded1979Price Target and Rating Average Stock Price Forecast$119.83 High Stock Price Forecast$173.00 Low Stock Price Forecast$85.00 Forecasted Upside/Downside+69.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.66 Trailing P/E Ratio107.43 Forward P/E Ratio14.29 P/E GrowthN/ANet Income$548.70 million Net Margins1.43% Pretax Margin2.15% Return on Equity7.65% Return on Assets4.33% Debt Debt-to-Equity Ratio0.46 Current Ratio1.66 Quick Ratio0.97 Sales & Book Value Annual Sales$3.16 billion Price / Sales1.50 Cash Flow$18.04 per share Price / Cash Flow3.93 Book Value$74.71 per share Price / Book0.95Miscellaneous Outstanding Shares66,791,000Free Float65,322,000Market Cap$4.74 billion OptionableOptionable Beta0.27 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Douglas C. Bryant (Age 65)Pres, CEO & Director Comp: $4.82MMr. Joseph M. Busky CPA (Age 55)Chief Financial Officer Comp: $1.47MMr. Robert J. Bujarski J.D. (Age 54)Exec. VP & COO Comp: $2.62MMs. Michelle A. Hodges (Age 63)Sr. VP & Gen. Counsel Comp: $1.8MDr. Werner Kroll Ph.D. (Age 66)Sr. VP of R&D Comp: $1.25MMs. Louise M. BrandySr. VP & Chief Information OfficerMr. Patrick E. KleinChief Admin. OfficerRuben ArguetaDirector of Investor RelationsMr. William J. Ferenczy (Age 67)Point of Care Bus. Unit Leader Mr. Michael S. Iskra (Age 53)Exec. VP & Chief Commercial Officer More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGLantheusNASDAQ:LNTHIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInstitutional OwnershipWolverine Trading LLCSold 2,700 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 16,200 shares on 8/22/2023Ownership: 0.024%John G Ullman & Associates Inc.Bought 450 shares on 8/21/2023Ownership: 0.048%Teachers Retirement System of The State of KentuckyBought 2,774 shares on 8/21/2023Ownership: 0.036%Osaic Holdings Inc.Sold 323 shares on 8/21/2023Ownership: 0.009%View All Institutional Transactions QDEL Stock - Frequently Asked Questions Should I buy or sell QuidelOrtho stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" QDEL shares. View QDEL analyst ratings or view top-rated stocks. What is QuidelOrtho's stock price forecast for 2023? 5 brokerages have issued 1 year price targets for QuidelOrtho's stock. Their QDEL share price forecasts range from $85.00 to $173.00. On average, they predict the company's stock price to reach $119.83 in the next twelve months. This suggests a possible upside of 69.0% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts. How have QDEL shares performed in 2023? QuidelOrtho's stock was trading at $85.67 at the beginning of 2023. Since then, QDEL shares have decreased by 17.2% and is now trading at $70.90. View the best growth stocks for 2023 here. When is QuidelOrtho's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our QDEL earnings forecast. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) posted its quarterly earnings results on Tuesday, August, 8th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.03. The firm earned $665.10 million during the quarter, compared to the consensus estimate of $615.11 million. QuidelOrtho had a net margin of 1.43% and a trailing twelve-month return on equity of 7.65%. The company's revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.11 earnings per share. What ETFs hold QuidelOrtho's stock? ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Ballast Small/Mid Cap ETF (MGMT) and Simplify Health Care ETF (PINK).iShares U.S. Medical Devices ETF (IHI). What guidance has QuidelOrtho issued on next quarter's earnings? QuidelOrtho issued an update on its FY 2023 earnings guidance on Wednesday, August, 9th. The company provided earnings per share (EPS) guidance of $4.85-$5.30 for the period, compared to the consensus estimate of $5.34. The company issued revenue guidance of $2.88 billion-$3.08 billion, compared to the consensus revenue estimate of $3.00 billion. What is Doug Bryant's approval rating as QuidelOrtho's CEO? 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM). What is QuidelOrtho's stock symbol? QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL." Who are QuidelOrtho's major shareholders? QuidelOrtho's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.50%), ArrowMark Colorado Holdings LLC (4.83%), Senvest Management LLC (4.65%), State Street Corp (2.33%), JPMorgan Chase & Co. (1.79%) and Geode Capital Management LLC (1.27%). Insiders that own company stock include Charles P Slacik, Douglas C Bryant, Mary Lake Ph D Polan, Werner Kroll, William J Ferenczy and William J Ferenczy. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is QuidelOrtho's stock price today? One share of QDEL stock can currently be purchased for approximately $70.90. How much money does QuidelOrtho make? QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $4.74 billion and generates $3.16 billion in revenue each year. The company earns $548.70 million in net income (profit) each year or $0.66 on an earnings per share basis. How many employees does QuidelOrtho have? The company employs 7,000 workers across the globe. How can I contact QuidelOrtho? QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (800) 874-1517, via email at rargueta@quidel.com, or via fax at 858-453-4338. This page (NASDAQ:QDEL) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.